{"result": "(\"entity\"<|>SUCRALFATO<|>ORGANIZATION<|>Sucralfato is a medication that can cause interactions with enteral nutrition, leading to complications such as obstruction of feeding tubes.)\n##\n(\"entity\"<|>ANTIÁCIDOS<|>ORGANIZATION<|>Antiácidos are medications that can interact with enteral nutrition and may lead to gastrointestinal issues.)\n##\n(\"entity\"<|>NUTRICIÓN ENTERAL<|>ORGANIZATION<|>Nutrición enteral refers to the method of delivering nutrients directly into the gastrointestinal tract, which can be affected by various medications.)\n##\n(\"entity\"<|>METOCLOPRAMIDA<|>ORGANIZATION<|>Metoclopramida is a procinético agent that promotes gastric emptying and intestinal motility, potentially improving tolerance to enteral nutrition.)\n##\n(\"entity\"<|>CISAPRIDA<|>ORGANIZATION<|>Cisapride is a medication that stimulates intestinal motility and can help with gastric emptying.)\n##\n(\"entity\"<|>GASTROENTERITIS INFECCIOSA<|>EVENT<|>Gastroenteritis infecciosa is an infectious condition that can be confused with intolerance to enteral nutrition due to similar gastrointestinal symptoms.)\n##\n(\"entity\"<|>TABLA 5<|>EVENT<|>Tabla 5 presents data on intolerance to enteral nutrition due to gastrointestinal problems related to medications.)\n##\n(\"relationship\"<|>SUCRALFATO<|>NUTRICIÓN ENTERAL<|>Sucralfato can cause interactions that lead to obstruction of feeding tubes in patients receiving enteral nutrition<|>8)\n##\n(\"relationship\"<|>ANTIÁCIDOS<|>NUTRICIÓN ENTERAL<|>Antiácidos can interact with enteral nutrition, potentially causing gastrointestinal complications<|>7)\n##\n(\"relationship\"<|>METOCLOPRAMIDA<|>NUTRICIÓN ENTERAL<|>Metoclopramida aids in gastric emptying, which can enhance tolerance to enteral nutrition<|>6)\n##\n(\"relationship\"<|>CISAPRIDA<|>NUTRICIÓN ENTERAL<|>Cisapride stimulates intestinal motility, improving the effectiveness of enteral nutrition<|>6)\n##\n(\"relationship\"<|>GASTROENTERITIS INFECCIOSA<|>NUTRICIÓN ENTERAL<|>Gastroenteritis infecciosa can mimic symptoms of intolerance to enteral nutrition, leading to misdiagnosis<|>5)\n##\n(\"relationship\"<|>TABLA 5<|>NUTRICIÓN ENTERAL<|>Tabla 5 provides insights into how medications can cause intolerance to enteral nutrition<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: físico-química: ocurre cuando la combinación del medicamento con el preparado nutricional ocasiona una alteración de las características físico-químicas (cambios en la viscosidad o textura, formación de precipitados, etc.) del preparado o de la forma farmacéutica. El resultado puede ser la oclusión de la sonda, alteraciones en la biodisponibilidad del fármaco y/o nutrientes, o bien inactivación de los mismos. Como ejemplo de este tipo de interacciones, se han descrito casos de obstrucción de la sonda de alimentación y producción de bezoares esofágicos en pacientes que recibían nutrición enteral asociado a sucralfato o a antiácidos. Se piensa que ocurre como consecuencia de una precipitación de las proteínas de la nutrición con las sales de aluminio18, que se vería favorecida en medio ácido. Por ello, se debe evitar la administración conjunta y lavar la sonda con 30 ml de agua antes y después de la administración. La administración de disoluciones de fármacos con valores de pH extremos (inferiores a 4 o superiores a 10) junto con la nutrición enteral también conlleva el riesgo de precipitación y la consiguiente obstrucción de la sonda. El riesgo es mayor para fórmulas enterales con proteínas completas que con las de proteínas hidrolizadas o aminoácidos. Las alternativas para administrar estos fármacos serían: emplear otras fórmulas, vías de administración o fármaco alternativo; o administrar el fármaco 1 hora antes o 2 horas después de la nutrición enteral.\n\nb) Incompatibilidad farmacéutica: se produce cuando la manipulación de la forma farmacéutica, para su administración a través de la sonda, tiene como consecuencia una modificación de la eficacia y/o de la tolerancia del fármaco13. Este tipo de incompatibilidad es especialmente relevante en el caso de formas farmacéuticas especiales, tales como formas de liberación sostenida, cubiertas entéricas, etc.\n\nc) Incompatibilidad fisiológica: en este tipo de interacción, y como consecuencia de un efecto no farmacológico del principio activo o alguno de sus componentes, se produce un descenso en la tolerancia al soporte nutricional12, 13. Se trata, en general, de alteraciones gastrointestinales (diarrea, distensión abdominal, etc.). Este tipo de interacción con frecuencia no se diagnostica, de modo que se atribuyen los síntomas a intolerancia a la nutrición enteral, gastroenteritis infecciosa, etc., y conduce frecuentemente a la suspensión del soporte nutricional. Las causas más frecuentes son la osmolalidad elevada y el alto contenido en sorbitol. La osmolalidad es una de las características físicas que más determinan la tolerancia del individuo a una disolución. Valores de osmolalidad próximos al de las secreciones intestinales (100-400 mOsm/kg H2O) son mejor tolerados. Hay formas farmacéuticas con valores de osmolalidad muy superiores (hasta 6.000 mOsm/kg H2O), que administrados sin diluir pueden provocar intolerancia, especialmente si se administran a gran velocidad o si la sonda se localiza en el duodeno o el yeyuno2. El sorbitol es un excipiente habitual en formulaciones líquidas, que actúa como saborizante y estabilizante. Cantidades elevadas del mismo (>10 g/día) pueden provocar aerofagia y distensión abdominal, e incluso si la cantidad es superior a 20 g/día, espasmos abdominales y diarrea.\n\nd) Incompatibilidad farmacológica: aparece una interacción de este tipo cuando, como consecuencia de un efecto farmacológico del medicamento, se produce alguna alteración a nivel gastrointestinal (pH, motilidad o secreciones gastrointestinales, náuseas o vómitos, diarrea, etc.) que puede alterar la tolerancia o absorción de la nutrición enteral (tabla 5).\n---\nTema 44. Interacción entre dieta y fármacos 713\n\nTabla 5. Intolerancia a la nutrición enteral por problemas gastrointestinales: Papel de los fármacos.\n\n1. Fármacos que retrasan el vaciamiento gástrico o disminuyen la motilidad gastrointestinal\n   - Fármacos con efecto anticolinérgico: relajan el músculo liso e inhiben la motilidad gástrica: antihistamínicos, antidepresivos tricíclicos, fenotiacinas, antiparkinsonianos\n   - Antiácidos que contengan aluminio\n   - Opiáceos\n\n2. Agentes procinéticos: favorecen el vaciamiento gástrico y estimulan la motilidad intestinal:\n   - Metoclopramida, cisaprid\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}